Description
Neratinib
Each film-coated tablet contains Neratinib maleate 48.31 mg equivalent to Neratinib … 40mg.
INDICATIONS
LuciNera is a kinase inhibitor indicated: • As a single agent, for the extended adjuvant treatment of adult patients with earlystage HER2-positive breast cancer, to follow adjuvant trastuzumab based therapy. • In combination with capecitabine, for the treatment of adult patients with advanced or metastatic HER2 -positive breast cancer who have received two or more prior anti – HER2 based regimens in the metastatic setting.
DOSAGE AND USE
• Extended adjuvant treatment of early -stage breast cancer: 240 mg (6 tablets) given orally once daily, with food, continuously until disease recurrence for up to one year. • Advanced or metastatic breast cancer: 240 mg (6 tablets) given orally once daily with food on Days 1-21 of a 21-day cycle plus capecitabine (750 mg/m2 given orally twice daily) on Days 1 -14 of a 21 -day cycle until disease progression or unacceptable toxicities. • Dose escalation: A two-week dose escalation for LuciNera may also be initiated. • Dose interruptions and/or dose reductions are recommended based on individual safety and tolerability. • Hepatic impairment: Reduce starting dose to 80 mg in patients with severe hepatic impairment.
STORAGE
In a dry place and store at 20℃ to 25℃.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNINGS
Keep medicine out of reach of Children. Do not administer LuciNera during Pregnancy and Lactation.
Reviews
There are no reviews yet.